Role of non‐esterified fatty acids in the pathogenesis of Type 2 diabetes mellitus

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Diabetic Medicine

• Publication date

  1998-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/(SICI)1096-9136(199805)15:5<360::AID-DIA568>3.0.CO;2-WPMID 9609356
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fat-induced changes in mouse pancreatic islet insulin secretion, insulin biosynthesis and glucose metabolism

  2004cited by this paper
• Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM

  1997influential reference
• The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study

  1997cited by this paper
• Long-Chain Fatty Acids Inhibit Acetyl-CoA Carboxylase Gene Expression in the Pancreatic β-Cell Line INS-1

  1997cited by this paper
• Role of nitric oxide in obesity-induced beta cell disease.

  1997influential reference
• Are the β-Cell Signaling Molecules Malonyl-CoA and Cystolic Long-Chain Acyl-CoA Implicated in Multiple Tissue Defects of Obesity and NIDDM?

  1996influential reference
• Does free fatty acid infusion impair insulin action also through an increase in oxidative stress?

  1996cited by this paper
• Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative.

  1995cited by this paper
• Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes.

  1995cited by this paper
• Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications

  1995influential reference
• An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).

  1995cited by this paper
• A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM

  1995cited by this paper
• Effects of a 48-h Fat Infusion on Insulin Secretion and Glucose Utilization

  1995cited by this paper
• Opposite effects of short- and long-term fatty acid infusion on insulin secretion in healthy subjects

  1995cited by this paper
• Free Fatty Acid as a Link in the Regulation of Hepatic Glucose Output by Peripheral Insulin

  1995cited by this paper
• Pancreatic beta-cells in obesity. Evidence for induction of functional, morphologic, and metabolic abnormalities by increased long chain fatty acids.

  1995cited by this paper
• Fatty acid-mediated effects on the glutathione redox cycle in cultured endothelial cells.

  1994cited by this paper
• Tumor Necrosis Factor α: A Key Component of the Obesity-Diabetes Link

  1994cited by this paper
• The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression.

  1994cited by this paper
• The peroxisome proliferator activated receptor regulates malic enzyme gene expression.

  1994cited by this paper
• Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle.

  1994cited by this paper
• Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.

  1994cited by this paper
• Mechanisms of fatty acid-induced inhibition of glucose uptake.

  1994cited by this paper
• Metabolic origin of insulin resistance in obesity with and without Type 2 (non-insulin-dependent) diabetes mellitus

  1993cited by this paper
• Peroxisome proliferator-activated receptors A link between endocrinology and nutrition?

  1993cited by this paper
• Contribution of muscle and liver to glucose-fatty acid cycle in humans.

  1993cited by this paper
• The relation between insulin sensitivity and the fatty-acid composition of skeletal-muscle phospholipids.

  1993cited by this paper
• Fatty acids are potent modulators of lactate utilization in isolated hepatocytes from fed rats.

  1993cited by this paper
• Chronic perifusion of rat islets with palmitate suppresses glucose-stimulated insulin release.

  1993cited by this paper
• Metabolic Effects of Suppression of Nonesterified Fatty Acid Levels With Acipimox in Obese NIDDM Subjects

  1992cited by this paper
• Estimation of Insulin Secretion Rates from C-Peptide Levels: Comparison of Individual and Standard Kinetic Parameters for C-Peptide Clearance

  1992influential reference
• Banting lecture 1990. Beta-cells in type II diabetes mellitus.

  1991cited by this paper
• Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus.

  1991cited by this paper
• Modulation of hepatic glucose production by non-esterified fatty acids in Type 2 (non-insulin-dependent) diabetes mellitus

  1991cited by this paper
• Demonstration of a novel feedback mechanism between FFA oxidation from intracellular and intravascular sources.

  1991cited by this paper
• Operation of Randle's Cycle in Patients With NIDDM

  1990cited by this paper
• Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents.

  1990cited by this paper
• Regulation of beta-cell glucose transporter gene expression.

  1990cited by this paper
• A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation.

  1990cited by this paper
• Time dependence of the interaction between lipid and glucose in humans.

  1989cited by this paper
• Control of hepatic gluconeogenesis: role of fatty acid oxidation.

  1989cited by this paper
• Insulin-membrane interactions and membrane fluidity changes.

  1987cited by this paper
• Relationship between insulin-mediated glucose disposal and lipid metabolism in man.

  1985cited by this paper
• Effect of fatty acids and ketones on the activity of pyruvate dehydrogenase in skeletal-muscle mitochondria.

  1983cited by this paper
• Epidemiology of diabetes mellitus.

  1974cited by this paper
• Influence of nicotinic acid on the rates of turnover and oxidation of plasma glucose in man.

  1973cited by this paper
• Feedback Inhibition of Key Glycolytic Enzymes in Liver: Action of Free Fatty Acids

  1966cited by this paper
• The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus.

  1963cited by this paper

• Residential Greenness and Subtypes of Gestational Diabetes Mellitus: A Metabolomic Investigation.

  2026cites this paper
• Effects of Saikosaponin-A on Insulin Resistance in Obesity: Computational and Animal Experimental Study.

  2024cites this paper
• The Immunomodulating Effect of Baicalin on Inflammation and Insulin Resistance in High-Fat-Diet-Induced Obese Mice

  2021cites this paper
• Association of Serum Adiponectin with Intima Media Thickness of Dorsalis Pedis Artery and Macroangiopathy in Type 2 Diabetes

  2020cites this paper
• Understanding the Link between Dairy Foods and Type 2 Diabetes: An Investigation Using Dairy Fatty Acid Biomarkers

  2018cites this paper
• Non-Immune Islet beta cell susceptibility to failure in NODk mice

  2017cites this paper
• Effect of insulin glargine on endogenous insulin secretion and beta-cell function in Japanese type 2 diabetic patients using oral antidiabetic drugs.

  2014cites this paper
• Effects of Metformin on the Regulation of Free Fatty Acids in Insulin Resistance: A Double-Blind, Placebo-Controlled Study

  2012cites this paper
• Effects of fatty acids on albumin-mediated cholesterol efflux from endothelial cells and on the growth of hamster pancreatic β-cells

  2010cites this paper
• Postprandial lipaemia, oxidative stress and endothelial function: a review

  2010cites this paper
• Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review.

  2010cites this paper
• Rosiglitazone Maleate and Metformin Hydrochloride in Fixed Combination: What Role in the Treatment of Type 2 Diabetes?

  2009cites this paper
• Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?

  2008cites this paper
• Clinical trials with thiazolidinediones in subjects with Type 2 diabetes – is pioglitazone any different from rosiglitazone?

  2008cites this paper
• Verbesserung der Insulinsensitivität - Möglichkeiten und Grenzen der Pharmakotherapie

  2008cites this paper
• Change in pancreatic B‐cell function (HOMA‐B) varies in different populations with similar genetic backgrounds but different environments

  2007cites this paper
• The different mechanisms of insulin sensitizers to prevent type 2 diabetes in OLETF rats

  2007cites this paper
• Leptin, skeletal muscle lipids, and lipid-induced insulin resistance.

  2007cites this paper
• Abnormal glucose tolerance and non-esterified fatty acids (NEFAs) as predictors of non-alcoholic steatohepatitis (NASH): which Ash that ignites the NASH.

  2007cites this paper
• Importancia de la prevención cardiovascular en la diabetes mellitus: un reto pendiente

  2006cites this paper
• Lipid metabolism and adipokine levels in fatty acid-binding protein null and transgenic mice.

  2006influential citation
• Chapter 14 Insulin resistance, inflammation, and the IKK/IκB/NF-κB pathway

  2006cites this paper
• Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study.

  2005cites this paper
• Plasma non-esterified fatty acids: why are we not measuring them routinely?

  2005cites this paper
• Diabetic dyslipidaemia: effective management reduces cardiovascular risk.

  2005cites this paper
• Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study.

  2004cites this paper
• In vivo regulation of plasma free fatty acids in insulin resistance.

  2004cites this paper
• Fatty Acid-induced Insulin Resistance in L6 Myotubes Is Prevented by Inhibition of Activation and Nuclear Localization of Nuclear Factor κB*

  2004cites this paper
• Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus.

  2004cites this paper
• Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea

  2004cites this paper
• Effects of dietary fatty acids on insulin sensitivity and secretion

  2004cites this paper
• Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm.

  2004cites this paper
• The case for insulin treatment early in type 2 diabetes.

  2004cites this paper
• Rosiglitazone in Type 2 diabetes mellitus: an evaluation in British Indo‐Asian patients

  2003cites this paper
• The role of intramuscular lipid in insulin resistance.

  2003cites this paper
• "Regulation der Lipolyse im Fett- und im Muskelgewebe - Bedeutung für die Pathogenese der Insulinresistenz. Klinische Untersuchungen mit der Mikrodialyse."

  2003cites this paper
• Fallo celular beta y progresión de la diabetes mellitus tipo 2

  2003cites this paper
• Regulation der Lipolyse im Fett- und im Muskelgewebe - Bedeutung für die Pathogenese der Insulinresistenz : Klinische Untersuchungen mit der Mikrodialyse

  2003cites this paper
• Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes

  2002cites this paper
• Interaction between specific fatty acids, GLP-1 and insulin secretion in humans

  2002cites this paper
• Impaired glucose tolerance and metformin: clinical and mechanistic aspects

  2002cites this paper
• Low-dose dexamethasone in the rat: a model to study insulin resistance.

  2002cites this paper
• Ultrasonographically assessed carotid atherosclerosis in Japanese type 2 diabetic patients: Role of nonesterified fatty acids.

  2002cites this paper
• Type 2 diabetes and atherosclerotic cardiovascular disease: do they share common antecedents?:

  2002cites this paper
• Effect of the Pattern of Elevated Free Fatty Acids on Insulin Sensitivity and Insulin Secretion in Healthy Humans

  2001cites this paper
• Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.

  2001cites this paper
• High prevalence of hypovitaminosis D in female type 2 diabetic population.

  2001cites this paper
• Clinical features of insulin resistance and beta cell dysfunction and the relationship to type 2 diabetes.

  2001cites this paper
• Insulin Resistance and Insulin Sensitizers

  2001cites this paper
• Insulin resistance and beta-cell function--a clinical perspective.

  2001cites this paper
• A Novel Use of the Hyperinsulinemic-Euglycemic Clamp Technique to Estimate Insulin Sensitivity of Systemic Lipolysis

  2001cites this paper
• Effect of experimental elevation of free fatty acids on insulin secretion and insulin sensitivity in healthy carriers of the Pro12Ala polymorphism of the peroxisome proliferator--activated receptor-gamma2 gene.

  2001cites this paper
• Serum nonesterified fatty acids are related with carotid atherosclerotic plaque in nonobese nonhypertensive Japanese type 2 diabetic patients.

  2001cites this paper
• Insulin resistance and beta-cell function - a clinical perspective.

  2001cites this paper
• PPARγ agonists in type 2 diabetes: how far have we come in ‘preventing the inevitable’? A review of the metabolic effects of rosiglitazone

  2001cites this paper
• PPAR gamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone.

  2001cites this paper
• Insulin resistance and β‐cell function – a clinical perspective

  2001cites this paper
• HMR389 89__95

  2001cites this paper
• Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

  2000cites this paper
• Addition of low‐dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients

  2000cites this paper
• Chronic infusion of norepinephrine into the VMH of normal rats induces the obese glucose-intolerant state.

  2000cites this paper
• Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes

  2000cites this paper
• Stimulatory effect of increased non-esterified fatty acid concentrations on proinsulin processing in healthy humans

  2000cites this paper
• Suppression of systemic, intramuscular, and subcutaneous adipose tissue lipolysis by insulin in humans.

  2000cites this paper
• Fatty acids and insulin secretion

  2000cites this paper
• Management of lipids: comparison between patients with diabetes and ischaemic heart disease

  2000cites this paper
• Reduced β-cell function contributes to impaired glucose tolerance in dogs made obese by high-fat feeding.

  1999cites this paper
• Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes.

  1999cites this paper
• Reduced b -cell function contributes to impaired glucose tolerance in dogs made obese by high-fat feeding

  1999cites this paper
• [Epidemiology of cardio-vascular complications of diabetes].

  1999cites this paper
• Reduced b -cell function contributes to impaired glucose tolerance in dogs made obese by high-fat feeding

  1999cites this paper
• Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve‐week, randomized, placebo‐controlled study

  1999cites this paper
• Le diabète de type 2 vu par l’épidémiologiste

  1998cites this paper
• Fatty acid composition of phospholipids and neutral lipids from human diabetic small arteries and veins by a new TLC method.

  1998cites this paper
• Lipids and diabetes: a fatal combination?

  1998cites this paper